Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 78c, Beats on Revenue; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 8, 2023 4:11 PM EST   Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY
Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of AGAMREE® License
Third Quarter 2023 Non-GAAP Net Income of $55.9 Million, $0.49 per Share Diluted
Reported U.S. FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy
sNDA Seeking to Increase FIRDAPSE® Maximum Daily Dose to 100 mg Accepted for Filing by the FDA
Two New... More
